Metformin limits osteoarthritis development and progression through activation of AMPK signalling

Ann Rheum Dis. 2020 May;79(5):635-645. doi: 10.1136/annrheumdis-2019-216713. Epub 2020 Mar 10.

Abstract

Objectives: In this study, we aim to determine the effect of metformin on osteoarthritis (OA) development and progression.

Methods: Destabilisation of the medial meniscus (DMM) surgery was performed in 10-week-old wild type and AMP-activated protein kinase (AMPK)α1 knockout (KO) mice. Metformin (4 mg/day in drinking water) was given, commencing either 2 weeks before or 2 weeks after DMM surgery. Mice were sacrificed 6 and 12 weeks after DMM surgery. OA phenotype was analysed by micro-computerised tomography (μCT), histology and pain-related behaviour tests. AMPKα1 (catalytic alpha subunit of AMPK) expression was examined by immunohistochemistry and immunofluorescence analyses. The OA phenotype was also determined by μCT and MRI in non-human primates.

Results: Metformin upregulated phosphorylated and total AMPK expression in articular cartilage tissue. Mild and more severe cartilage degeneration was observed at 6 and 12 weeks after DMM surgery, evidenced by markedly increased Osteoarthritis Research Society International scores, as well as reduced cartilage areas. The administration of metformin, commencing either before or after DMM surgery, caused significant reduction in cartilage degradation. Prominent synovial hyperplasia and osteophyte formation were observed at both 6 and 12 weeks after DMM surgery; these were significantly inhibited by treatment with metformin either before or after DMM surgery. The protective effects of metformin on OA development were not observed in AMPKα1 KO mice, suggesting that the chondroprotective effect of metformin is mediated by AMPK signalling. In addition, we demonstrated that treatment with metformin could also protect from OA progression in a partial medial meniscectomy animal model in non-human primates.

Conclusions: The present study suggests that metformin, administered shortly after joint injury, can limit OA development and progression in injury-induced OA animal models.

Keywords: arthritis; chondrocytes; osteoarthritis; treatment.

MeSH terms

  • AMP-Activated Protein Kinases / genetics*
  • Animals
  • Cartilage, Articular / drug effects*
  • Cartilage, Articular / pathology
  • Cells, Cultured
  • Chondrocytes / drug effects
  • Chondrocytes / pathology
  • Disease Models, Animal
  • Disease Progression
  • Gene Expression Regulation
  • Humans
  • Hypoglycemic Agents / pharmacology
  • Menisci, Tibial / pathology
  • Menisci, Tibial / surgery
  • Metformin / pharmacology*
  • Mice
  • Mice, Knockout
  • Mice, Obese
  • Osteoarthritis / drug therapy*
  • Osteoarthritis / pathology
  • Random Allocation
  • Sensitivity and Specificity
  • Signal Transduction / genetics
  • Up-Regulation / genetics*

Substances

  • Hypoglycemic Agents
  • Metformin
  • AMP-Activated Protein Kinases